Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces that it
has commenced an underwritten public offering of shares of its common
stock. Rocket also intends to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of its common stock sold
in the public offering. All the shares in the offering are to be sold by
Rocket. The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be completed, or the
actual size or terms of the offering.
Rocket intends to use the net proceeds from the offering to further fund
the development of its pipeline of gene therapies for rare diseases, to
accelerate the buildout of in-house manufacturing capabilities, and for
general corporate purposes.
SVB Leerink, Evercore ISI and William Blair are acting as the
joint-bookrunning managers for the public offering.
The public offering is being made by Rocket pursuant to an effective
shelf registration statement on Form S-3 that was previously filed with
the U.S. Securities and Exchange Commission (the “SEC”) and declared
effective by the SEC. A preliminary prospectus supplement relating to
and describing the terms of the offering will be filed with the SEC.
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may be obtained
from SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525,
ext. 6132, or by email syndicate@svbleerink.com;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200,
or by email at ecm.prospectus@evercore.com;
and William Blair & Company, L.L.C., Attention: Prospectus Department,
150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800)
621-0687, or by email at prospectus@williamblair.com.
You may also obtain these documents free of charge by visiting the SEC’s
website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Forward-looking Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding the consummation of the offering, the
terms of the offering, and the satisfaction of customary closing
conditions with respect to the offering and the anticipated use of the
net proceeds of the offering, may constitute forward-looking statements
for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal securities
laws and are subject to substantial risks, uncertainties and
assumptions. You should not place reliance on these forward-looking
statements, which often include words such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,”
“suggest,” “target,” “will,” “will give,” “would,” or similar terms,
variations of such terms or the negative of those terms. Although Rocket
believes that the expectations reflected in the forward-looking
statements are reasonable, Rocket cannot guarantee such outcomes. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including, without limitation, changes as a result of market conditions
or for other reasons, the risk that the offering will not be
consummated, and the impact of general economic, industrial or political
conditions in the United States or internationally, as well as those
risks more fully discussed in the section entitled “Risk Factors” in
Rocket's Annual Report on Form 10-K for the year ended December 31,
2018. Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of the
date made, and Rocket undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190415005810/en/
Copyright Business Wire 2019